Randomized trial shows Nerandomilast improves alveolar repair in a mouse model of pulmonary fibrosis, indicating its therapeutic potential.
Key Points
The study aims to explore the effects of Nerandomilast on the differentiation of alveolar epithelial cells and its role in attenuating pulmonary fibrosis.
Pulmonary fibrosis was induced in C57BL/6 mice using intratracheal bleomycin administration.
Nerandomilast (12.5 mg/kg) was orally administered daily starting 7 days post-BLM, with lung analysis conducted on days 0, 7, 10, 14, and 21.
Fibrosis severity was assessed through hydroxyproline content measurement and histological scoring.
Nerandomilast treatment significantly attenuated BLM-induced pulmonary fibrosis by reducing hydroxyproline content and histological fibrosis scores compared to controls.
Lineage-tracing revealed a decrease in AT2 cells and an increase in KRT8+ transitional epithelial cells by day 10 after BLM exposure.
Nerandomilast enhanced differentiation into AT1 (PDPN+) cells while reducing differentiation into KRT8+ epithelial cells.